Central serous chorioretinopathy

Ophthalmologica

Volumn 232, Issue 2, 2014, Pages 65-76

  Liegl, Raffael ^a   Ulbig, Michael W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Central serous chorioretinopathy; Epidemiology; Pathogenesis; Risk factors

Indexed keywords

CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; MINERALOCORTICOID ANTAGONIST;

AUTOFLUORESCENCE IMAGING; CENTRAL SEROUS RETINOPATHY; DIAGNOSTIC TEST; DISEASE SEVERITY; EPIDEMIC; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHOTODYNAMIC THERAPY; REVIEW; RISK FACTOR; SCOTOMA; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; CENTRAL SEROUS CHORIORETINOPATHY;

CENTRAL SEROUS CHORIORETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; LASER COAGULATION; RISK FACTORS;

EID: 84925284014     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000360014     Document Type: Review

References (127)

1. von Graefe A: Über zentrale rezidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol 1866; 12: 211-215.
2. Horniker E: Über eine Form von zentraler Retinitis auf angioneurotischer Grundlage (Retinitis centralis angioneurotica). Graefes Arch Clin Exp Ophthalmol 1929; 123: 286-360.
3. Horniker E: Su di una forma retinite centrale di origine vasoneurotica (retinite central capillaro spastica). Ann Ottal 1927; 55: 578-600.
4. Gifford SR, Marquardt G: Central angiospastic retinopathy. Arch Ophthalmol 1939; 21: 211-228.
5. Maumenee AE: Macular diseases: clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol 1965; 69: 605-613.
6. Gass JD: Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967; 63(suppl):1-139.
7. Meyerle CB, Spaide RF: Central serous chorioretinopathy; in Albert DM, Miller JW, Azar DT, Blodi BA (eds): Albert and Jakobiec's Principles and Practice of Ophthalmology. Philadelphia, Saunders, 2008, vol 3, pp 1871-1880.
8. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M: Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126-145.
9. Spitznas M, Huke J: Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1987; 225: 437-440.
10. Castro-Correia J, Coutinho MF, Rosas V, Maia J: Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992; 81: 379-386.
11. Wang M, Sander B, la Cour M, Larsen M: Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta Ophthalmol Scand 2005; 83: 691-696.
12. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA: Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999; 128: 63-68.
13. Gilbert CM, Owens SL, Smith PD, Fine SL: Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984; 68: 815-820.
14. Jamil AZ, Mirza KA, Qazi ZU, Iqbal W, Khaliq J, Fawad-ur R, Ahmed A: Features of central serous chorioretinopathy presenting at a tertiary care hospital in Lahore. J Pak Med Assoc 2013; 63: 478-482.
15. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP: The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008; 115: 169-173.
16. Spaide RF: Central serous chorioretinopathy; in Krieglstein GK, Weinreb RN (eds): Medical Retina. Heidelberg, Springer, 2005, pp 77-95.
17. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079, discussion 2079-2080.
18. Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB, Chan WL: Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One 2013; 8:e66858.
19. Gäckle HC, Lang GE, Freissler KA, Lang GK: Central serous chorioretinopathy: clinical, fluorescein angiography and demographic aspects (in German). Ophthalmologe 1998; 95: 529-533.
20. Kim YC, Kim SD, Kim KS: A case of idiopathic central serous chorioretinopathy in a 12-year-old male treated with bevacizumab. Korean J Ophthalmol 2012; 26: 391-393.
21. Alwassia AA, Adhi M, Duker JS: Bilateral simultaneous central serous chorioretinopathy in a teenage girl with systemic arterial hypertension. Int Ophthalmol 2013; 33: 79-82.
22. Chan WM, Lai TY, Tano Y, Liu DT, Li KK, Lam DS: Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmol 2006; 50: 161-169.
23. Yannuzzi LA: Type-A behavior and central serous chorioretinopathy. Retina 1987; 7: 111-131.
24. Balo KP, Mihluedo H: Idiopathic central serous chorioretinopathy: two case reports observed in Togo (in French). Med Trop (Mars) 1996; 56: 381-383.
25. Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK: Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 2007; 245: 460-463.
26. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR: Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003; 95: 553-559.
27. Nicholson B, Noble J, Forooghian F, Meyerle C: Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126.
28. Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T: Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina 1999; 19: 12-21.
29. Yannuzzi LA: Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; 149: 361-363.
30. Okushiba U, Takeda M: Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography (in Japanese). Nihon Ganka Gakkai Zasshi 1997; 101: 74-82.
31. Prünte C, Flammer J: Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121: 26-34.
32. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996; 16: 203-213.
33. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112: 1057-1062.
34. Hayashi K, Hasegawa Y, Tokoro T: Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986; 9: 37-41.
35. Scheider A, Nasemann JE, Lund OE: Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. Am J Ophthalmol 1993; 115: 50-56.
36. Hussain D, Gass JD: Idiopathic central serous chorioretinopathy. Ind J Ophthalmol 1998; 46: 131-137.
37. Slakter JS, Yannuzzi LA, Guyer DR, Sorenson JA, Orlock DA: Indocyanine-green angiography. Curr Opin Ophthalmol 1995; 6: 25-32.
38. Gupta V, Gupta P, Dogra MR, Gupta A: Spontaneous closure of retinal pigment epithelium microrip in the natural course of central serous chorioretinopathy. Eye (Lond) 2010; 24: 595-599.
39. Goldstein BG, Pavan PR: 'Blow-outs' in the retinal pigment epithelium. Br J Ophthalmol 1987; 71: 676-681.
40. Piccolino FC, Borgia L: Central serous chorioretinopathy and indocyanine green angiography. Retina 1994; 14: 231-242.
41. Piccolino FC, Borgia L, Zinicola E, Zingirian M: Indocyanine green angiographic findings in central serous chorioretinopathy. Eye (Lond) 1995; 9: 324-332.
42. Spitznas M: Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 321-324.
43. Bouzas EA, Karadimas P, Pournaras CJ: Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448.
44. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S: Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111: 244-249.
45. Sun J, Tan J, Wang Z, Yang H, Zhu X, Li L: Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 313-316.
46. Thoelen AM, Bernasconi PP, Schmid C, Messmer EP: Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina 2000; 20: 98-99.
47. Loo JL, Lee SY, Ang CL: Can long-term corticosteroids lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids. Ann Acad Med Singapore 2006; 35: 496-499.
48. Polak BC, Baarsma GS, Snyers B: Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 1995; 79: 922-925.
49. Browning DJ: Nadolol in the treatment of central serous retinopathy. Am J Ophthalmol 1993; 116: 770-771.
50. Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI: Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993; 111: 1229-1233.
51. Garg SP, Dada T, Talwar D, Biswas NR: Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997; 81: 962-964.
52. Barnes PJ: Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426.
53. Sakaue M, Hoffman BB: Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991; 88: 385-389.
54. Oikarinen AI, Uitto J, Oikarinen J: Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol 1986; 64: 221-230.
55. Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H: Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005; 83: 132-133.
56. Baumal CR, Martidis A, Truong SN: Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. Arch Ophthalmol 2004; 122: 926-928.
57. Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, Brown B, Thompson L, Rabin DD, Breall WS, et al: Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: summary results of the recurrent coronary prevention project. Am Heart J 1986; 112: 653-665.
58. Errera MH, Kohly RP, da Cruz L: Pregnancyassociated retinal diseases and their management. Surv Ophthalmol 2013; 58: 127-142.
59. Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA: Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo) 2012; 67: 1047-1052.
60. Eom Y, Oh J, Kim SW, Huh K: Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol 2012; 26: 260-264.
61. Weenink AC, Borsje RA, Oosterhuis JA: Familial chronic central serous chorioretinopathy. Ophthalmologica 2001; 215: 183-187.
62. Spahn C, Wiek J, Burger T, Hansen L: Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 704-708.
63. Fawzi AA, Holland GN, Kreiger AE, Heckenlively JR, Arroyo JG, Cunningham ET Jr: Central serous chorioretinopathy after solid organ transplantation. Ophthalmology 2006; 113: 805-813e5.
64. Kanski J, Bowling B: Clinical Ophthalmology: A Systemic Approach. London, Elsevier, 2011.
65. Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A: Long-term results of halfdose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond) 2013; 27: 612-620.
66. Lim SH, Chang W, Sagong M: Efficacy of halffluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond) 2013; 27: 353-362.
67. Chen SN, Hwang JF, Tseng LF, Lin CJ: Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 2008; 115: 2229-2234.
68. Ficker L, Vafidis G, While A, Leaver P: Longterm follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-834.
69. Fok AC, Chan PP, Lam DS, Lai TY: Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 2011; 46: 160-163.
70. Gueudry J, Genevois O, Adam PA, Muraine M, Brasseur G: Retinal pigment epithelium tear following central serous chorioretinopathy. Acta Ophthalmol 2009; 87: 691-693.
71. Ishida Y, Kato T, Minamoto A, Yokoyama T, Jian K, Mishima HK: Retinal pigment epithelial tear in a patient with central serous chorioretinopathy treated with corticosteroids. Retina 2004; 24: 633-636.
72. Akiyama K, Kawamura M, Ogata T, Tanaka E: Retinal vascular loss in idiopathic central serous chorioretinopathy with bullous retinal detachment. Ophthalmology 1987; 94: 1605-1609.
73. Gass JD: Bullous retinal detachment: an unusual manifestation of idiopathic central serous choroidopathy. Am J Ophthalmol 1973; 75: 810-821.
74. Friberg TR, Eller AW: Serous retinal detachment resembling central serous chorioretinopathy following organ transplantation. Graefes Arch Clin Exp Ophthalmol 1990; 228: 305-309.
75. Shahin MM: Angiographic characteristics of central serous chorioretinopathy in an Egyptian population. Int J Ophthalmol 2013; 6: 342-345.
76. Yanuzzi L: The Retinal Atlas. Philadelphia, Saunders, 2010.
77. Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A: Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 709-712.
78. Stanga PE, Lim JI, Hamilton P: Indocyanine green angiography in chorioretinal diseases: indications and interpretation-an evidencebased update. Ophthalmology 2003; 110: 15-21, quiz 22-23.
79. Shiraki K, Moriwaki M, Matsumoto M, Yanagihara N, Yasunari T, Miki T: Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol 1997; 21: 245-253.
80. Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S: Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 2013; 33: 316-323.
81. Shin JY, Woo SJ, Yu HG, Park KH: Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011; 31: 119-126.
82. Hee MR, Puliafito CA, Wong C, Reichel E, Duker JS, Schuman JS, Swanson EA, Fujimoto JG: Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol 1995; 120: 65-74.
83. Yang L, Jonas JB, Wei W: Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 2013; 91:e358-e362.
84. Ahn SE, Oh J, Oh JH, Oh IK, Kim SW, Huh K: Three-dimensional configuration of subretinal fluid in central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2013; 54: 5944-5952.
85. Imamura Y, Fujiwara T, Margolis R, Spaide RF: Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-1473.
86. Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T: Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011; 31: 1603-1608.
87. Brandl C, Helbig H, Gamulescu MA: Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol 2014; 34: 7-13.
88. Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N: Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012; 119: 1666-1678.
89. Matsumoto H, Kishi S, Otani T, Sato T: Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008; 145: 162-168.
90. Kim SW, Oh J, Huh K: Correlations among various functional and morphological tests in resolved central serous chorioretinopathy. Br J Ophthalmol 2012; 96: 350-355.
91. Ojima Y, Hangai M, Sasahara M, Gotoh N, Inoue R, Yasuno Y, Makita S, Yatagai T, Tsujikawa A, Yoshimura N: Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using highspeed optical coherence tomography. Ophthalmology 2007; 114: 2197-2207.
92. Almeida A, Kaliki S, Shields CL: Autofluorescence of intraocular tumours. Curr Opin Ophthalmol 2013; 24: 222-232.
93. Hopkins J, Walsh A, Chakravarthy U: Fundus autofluorescence in age-related macular degeneration: an epiphenomenon? Invest Ophthalmol Vis Sci 2006; 47: 2269-2271.
94. Göbel AP, Fleckenstein M, Schmitz-Valckenberg S, Brinkmann CK, Holz FG: Imaging geographic atrophy in age-related macular degeneration. Ophthalmologica 2011; 226: 182-190.
95. Feeney L: Lipofuscin and melanin of human retinal pigment epithelium: fluorescence, enzyme cytochemical, and ultrastructural studies. Invest Ophthalmol Vis Sci 1978; 17: 583-600.
96. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ: In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995; 36: 718-729.
97. Delori FC, Staurenghi G, Arend O, Dorey CK, Goger DG, Weiter JJ: In vivo measurement of lipofuscin in Stargardt's disease-fundus flavimaculatus. Invest Ophthalmol Vis Sci 1995; 36: 2327-2331.
98. Wolf G: Lipofuscin, the age pigment. Nutr Rev 1993; 51: 205-206.
99. Spaide RF, Klancnik JM Jr: Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005; 112: 825-833.
100. von Ruckmann A, Fitzke FW, Fan J, Halfyard A, Bird AC: Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 2002; 133: 780-786.
101. Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA: Acute central serous chorioretinopathy and fundus autofluorescence. Retina 2005; 25: 989-993.
102. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK: Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-1458.
103. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM: Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752-763.
104. Taban M, Boyer DS, Thomas EL, Taban M: Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004; 137: 1073-1080.
105. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT: Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005; 112: 2088-2094.
106. Koytak A, Erol K, Coskun E, Asik N, Öztürk H, Özertürk Y: Fluorescein angiographyguided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010; 30: 1698-1703.
107. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS: Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006; 90: 869-874.
108. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS: Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008; 28: 85-93.
109. Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T: One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 2011; 31: 1921-1927.
110. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS: Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756-1765.
111. Lim JW, Kang SW, Kim YT, Chung SE, Lee SW: Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011; 95: 514-517.
112. Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H: Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond) 2012; 26: 640-649.
113. Brinkmann R, Roider J, Birngruber R: Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 2006; 302: 51-69.
114. Roider J, Michaud NA, Flotte TJ, Birngruber R: Response of the retinal pigment epithelium to selective photocoagulation. Arch Ophthalmol 1992; 110: 1786-1792.
115. Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J: Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 2011; 95: 83-88.
116. Brinkmann R, Schüle G, Neumann J, Framme C, Pörksen E, Elsner H, Theisen-Kunde D, Roider J, Birngruber R: Selective retina therapy: methods, technique, and online dosimetry (in German). Ophthalmologe 2006; 103: 839-849.
117. Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J: Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1638-1645.
118. Klatt C, Elsner H, Pörksen E, Brinkmann R, Bunse A, Birngruber R, Roider J: Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium (in German). Ophthalmologe 2006; 103: 850-855.
119. Leaver P, Williams C: Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979; 63: 674-677.
120. Robertson DM, Ilstrup D: Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983; 95: 457-466.
121. Yap EY, Robertson DM: The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol 1996; 114: 689-692.
122. Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K: Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992; 2: 103-114.
123. Gonzalez C: Serous retinal detachment: value of acetazolamide (in French). J Fr Ophtalmol 1992; 15: 529-536.
124. Pikkel J, Beiran I, Ophir A, Miller B: Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723-1725.
125. Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny JC, Jaisser F, Farman N, Behar-Cohen F: The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in Müller glial cells. FASEB J 2010; 24: 3405-3415.
126. Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F: Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012; 122: 2672-2679.
127. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F: Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2013; 33: 2096-2102.